In:
Cancer Science, Wiley, Vol. 103, No. 9 ( 2012-09), p. 1625-1630
Abstract:
In the present study, we evaluated the safety and effectiveness of SYT ‐ SSX ‐derived peptide vaccines in patients with advanced synovial sarcoma. A 9‐mer peptide spanning the SYT ‐ SSX fusion region ( B peptide) and its HLA ‐ A *2402 anchor substitute ( K 9I) were synthesized. In P rotocols A 1 and A 2, vaccines with peptide alone were administered subcutaneously six times at 14‐day intervals. The B peptide was used in P rotocol A 1, whereas the K 9I peptide was used in P rotocol A 2. In P rotocols B 1 and B 2, the peptide was mixed with incomplete F reund's adjuvant and then administered subcutaneously six times at 14‐day intervals. In addition, interferon‐α was injected subcutaneously on the same day and again 3 days after the vaccination. The B peptide and K 9I peptide were used in P rotocols B 1 and B 2, respectively. In total, 21 patients (12 men, nine women; mean age 43.6 years) were enrolled in the present study. Each patient had multiple metastatic lesions of the lung. Thirteen patients completed the six‐injection vaccination schedule. One patient developed intracerebral hemorrhage after the second vaccination. Delayed‐type hypersensitivity skin tests were negative in all patients. Nine patients showed a greater than twofold increase in the frequency of CTL s in tetramer analysis. Recognized disease progression occurred in all but one of the nine patients in P rotocols A 1 and A 2. In contrast, half the 12 patients had stable disease during the vaccination period in P rotocols B 1 and B 2. Of note, one patient showed transient shrinkage of a metastatic lesion. The response of the patients to the B protocols is encouraging and warrants further investigation.
Type of Medium:
Online Resource
ISSN:
1347-9032
,
1349-7006
DOI:
10.1111/cas.2012.103.issue-9
DOI:
10.1111/j.1349-7006.2012.02370.x
Language:
English
Publisher:
Wiley
Publication Date:
2012
detail.hit.zdb_id:
2115647-5
detail.hit.zdb_id:
2111204-6
Bookmarklink